A High-Throughput Cell-based Drug Discovery System

高通量细胞药物发现系统

• 批准号: 6485791
• 负责人: Rajan Kumar
• 金额: $ 25万
• 依托单位: GENOME DATA SYSTEMS, INC.
• 依托单位国家: 美国
• 财政年份: 2002
• 资助国家: 美国
• 起止时间: 2002-06-15 至 2003-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6485791
• 关键词: apoptosis; biomedical automation; biotechnology; consumable /disposable biomedical equipment; cytology; drug discovery /isolation; fluid flow; fluorescence microscopy; genome; high throughput technology; pharmacogenetics; technology /technique development; tissue /cell culture; apoptosis; biomedical automation; biotechnology; consumable /disposable biomedical equipment; cytology; drug discovery /isolation; fluid flow; fluorescence microscopy; genome; high throughput technology; pharmacogenetics; technology /technique development; tissue /cell culture

DESCRIPTION (provided by applicant): There is a need to expand the use of cell-based assays in high throughput screening systems for diabetes research as well as research into other digestive systems diseases. Genome Data Systems, Inc. (GDS) proposes to design, fabricate and commercialize a high throughput drug discovery system based on its proprietary fluidic chip technology. In this approach, the cell growth and assay are separated into two modules and growth of cells for prolonged periods in small volumes is not required. Moreover, the disposable components are simple-to-fabricate and are inexpensive, while the more expensive chips can be reused. The technology lends itself to development of compact high throughput screening instruments. GDS is assembling a team of experts in microfluidics, micro-fabrication, detection optics and genomics to ensure success of this project. This SBIR project is focused on the design and fabrication of a high throughput screening instrument for apoptosis assays with an integrated generic fluidic chip and other necessary components. The proposed commercial applications of such technology include drug discovery for the NIDDK focus areas; however, the technology will have broad applications in drug discovery in other therapeutic areas as well. At the successful development of GeneCard and GeneCube, GDS will manufacture them for commercialization and wide distribution to genomic research community. PROPOSED COMMERCIAL APPLICATION: Current commercial applications of the proposed instruments and microfluidics chips include drug discovery, chemical detection, diagnostic testing, genomics, proteomics, and pharmaceutical research.

描述（由申请人提供）：有必要扩展 用于糖尿病研究的高通量筛查系统中的基于细胞的测定 以及对其他消化系统疾病的研究。基因组数据系统， Inc.（GDS）提议设计，制造和商业化高通量 基于其专有液体芯片技术的药物发现系统。在这个 方法，细胞生长和测定分为两个模块和生长 不需要小体积长时间的细胞。而且， 一次性组件是简单的，价格便宜，而 更昂贵的芯片可以重复使用。该技术适合开发 紧凑的高吞吐量筛选工具。 GD正在组建一个团队 微流体，微型制作，检测光学和基因组学专家 确保该项目的成功。这个SBIR项目专注于设计和 用高吞吐量筛选仪器制造用于凋亡测定法 集成的通用液体芯片和其他必要组件。提议 这种技术的商业应用包括NIDDK的药物发现 焦点区域；但是，该技术将在药物中广泛应用 在其他治疗领域的发现。成功发展 GENCARD和GENECUBE，GDS将制造它们以进行商业化和广泛 分配给基因组研究界。 拟议的商业应用：拟议仪器和微流体芯片的当前商业应用包括药物发现，化学检测，诊断测试，基因组学，蛋白质组学和药物研究。